NervGen Appoints Shamim Ruff and Christine McSherry to Lead NVG-291 Development Path
NervGen named Shamim Ruff Chief Regulatory Affairs Officer to steer NVG-291’s approval strategy, leveraging her 30-year regulatory leadership at Stoke Therapeutics and Sarepta Therapeutics. The company also appointed Christine McSherry as SVP of Patient Advocacy and Clinical Affairs to integrate patient perspectives as NVG-291 advances toward Phase 3 trials.
1. Leadership Appointments and Roles
NervGen has appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as Senior Vice President of Patient Advocacy and Clinical Affairs. These strategic hires aim to strengthen the company’s leadership team during the critical execution phase for its lead candidate, NVG-291.
2. Regulatory Strategy for NVG-291
Shamim Ruff brings over 30 years of experience leading regulatory affairs at Stoke Therapeutics, Sarepta Therapeutics and major pharma companies. She will oversee NVG-291’s pathway to approval, including FDA Fast Track and EMA Orphan Drug designations and preparation for a Phase 3 clinical trial.
3. Patient Advocacy and Clinical Development
Christine McSherry has more than three decades of experience in patient-focused drug development, having co-founded Casimir and led the Jett Foundation’s advocacy efforts. She will ensure that clinical programs for NVG-291 reflect the needs and insights of individuals living with spinal cord injury.